Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesBio-Gene Technology Ltd

Bio-Gene Technology Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.015 AUD -0.00 ( 6.25%)
Last update at 2026-11-12T04:52:00Z
VOLUME
13845
Market Cap
5.69M

Momentum Score

…

Bio-Gene Technology Limited, an agtech development company, engages in the development and commercialization of naturally derived insecticide products in Australia and internationally. Its products include Flavocide, a synthetically produced nature-identical compound; and Qcide, a natural plant-derived oil with high levels of tasmanone. The company has a research collaboration agreement with James Cook University for experiments demonstrating the value of pre-conditioning biomass prior to distillation; Cesar for assessing the insecticidal activity of its molecules against a range of insect species; Advanced Molecular Technologies; CSIRO for a chemistry development process; the Department of Agriculture and Fisheries, Queensland Government for assessing activity against grain storage pests; Eurofins; Grain Research Development Corporation; Pacific Discovery Services; Purdue University; Southern Cross University for chemical analysis of natural products; University of Florida; and University of Technology. It serves animal health, crop protection, grain storage, public health, and consumer applications. The company was incorporated in 1995 and is based in Melbourne, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.01
Low
0.01
High
52 Week Price Range
0.01
Low
0.05
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Publicly listed on the ASX, Bio-Gene Technology Ltd is an Australian biotechnology company with limited publicly available information about its operations and product portfolio. Long-term growth may be driven by successful research and development, regulatory approvals, strategic partnerships and commercialisation, and investors may find exposure to early-stage biotech upside attractive if those milestones are achieved.

Principal investment risks include high execution and regulatory uncertainty typical of early-stage biotech, likely need for additional financing and dilution, limited market liquidity and dependence on successful product development.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.02
Dividend Yield
-
Revenue TTM
1.08M
Revenue Per Share
0.00
Gross Profit TTM
-0.34M
Debt / Equity
-
ROE
-125.40%
Net Debt
-1.94M
ROCE
-162.77%
Diluted EPS TTM
-0.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -2.80M -2.58M -3.01M -3.10M -2.91M
Net income -2.33M -2.58M -2.41M -3.10M -2.80M
Selling general administrative - 0.88M 1.42M 0.48M 0.51M
Selling and marketing expenses - 0.56M 0.27M - -
Gross profit -0.04M -0.25M -0.30M 0.60M 0.88M
Reconciled depreciation - 0.04M 0.04M 0.05M 0.04M
Ebit -3.41M -2.62M -3.01M -3.18M -2.97M
Ebitda -3.36M -2.58M -2.97M -3.14M -2.93M
Depreciation and amortization 0.04M 0.04M 0.04M 0.05M 0.04M
Operating income -3.41M -3.07M -3.06M -3.18M -2.97M
Other operating expenses 3.41M 3.07M 3.08M 3.78M 3.85M
Interest expense - - - - 0.05M
Tax provision - 0.00M 0.00M 0.00M 0.00M
Interest income - 0.04M 0.09M 0.09M 0.05M
Net interest income - 0.04M 0.09M 0.09M 0.05M
Income tax expense -0.47M -0.39M -0.60M -0.09M -0.11M
Total revenue - 0.43M 0.02M 0.60M 0.88M
Total operating expenses 3.36M 2.82M 2.76M 3.78M 3.85M
Cost of revenue 0.04M 0.25M 0.32M - -
Total other income expense net 0.61M 0.48M 0.05M 0.00M 0.06M
Net income from continuing ops - -2.58M -2.41M -3.10M -2.91M
Net income applicable to common shares - -2.58M -2.41M -3.10M -2.91M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 2.61M 2.15M 3.16M 3.84M 7.30M
Intangible assets 0.13M 0.17M - 0.24M 0.28M
Other current assets 0.13M 0.07M 0.20M 0.07M 0.07M
Total liab 0.52M 0.52M 0.37M 0.61M 1.03M
Total stockholder equity 2.09M 1.63M 2.79M 3.22M 6.27M
Other current liab 0.29M 0.05M 0.30M 0.46M 0.79M
Common stock 25.71M - 21.52M 19.55M 19.55M
Capital stock - 22.94M - 19.55M 19.55M
Retained earnings -24.20M -22.03M -19.64M -17.43M -14.50M
Other liab - - - - 0.03M
Cash 1.94M 1.14M 0.71M 2.99M 6.34M
Total current liabilities 0.52M 0.51M 0.35M 0.57M 1.01M
Net debt -1.94M - -0.71M -2.99M -6.34M
Short term debt - - - 0.00M 0.00M
Other stockholder equity - - - 0.82M 1.22M
Property plant equipment - - - 0.01M 0.02M
Total current assets 2.47M 1.97M 2.94M 3.58M 7.00M
Net tangible assets - - - - 5.99M
Short term investments - - 1.50M - 0.07M
Net receivables 0.41M - 0.52M 0.45M 0.44M
Long term debt - - - 0.00M 0.00M
Inventory - - - 0.07M 0.15M
Accounts payable 0.22M 0.08M 0.05M 0.12M 0.22M
Accumulated other comprehensive income 0.58M - 0.91M 1.11M 1.22M
Non currrent assets other - - 0.20M - -
Non current assets total 0.14M 0.18M 0.22M 0.25M 0.30M
Long term debt total - - - 0.00M 0.00M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - 0.00M -0.01M - -0.01M
Change to liabilities - - - - 0.32M
Total cashflows from investing activities - 0.00M -0.01M 0.00M -0.01M
Net borrowings - - - - -0.07M
Total cash from financing activities 2.74M 1.47M 1.98M -0.07M 4.41M
Change to operating activities - - - - -0.02M
Net income -2.33M -2.58M -2.41M -3.10M -2.91M
Change in cash 1.30M -1.07M -0.78M -3.35M 2.41M
Begin period cash flow 0.64M 2.21M 2.99M 6.34M 3.93M
End period cash flow 1.94M 1.14M 2.21M 2.99M 6.34M
Total cash from operating activities -1.94M -2.54M -2.75M -3.28M 0.04M
Issuance of capital stock - 1.50M 2.03M - 4.72M
Depreciation 0.04M 0.04M 0.04M - 0.04M
Other cashflows from investing activities - - - 0.00M 0.00M
Change to account receivables 0.06M 0.03M -0.10M - 0.09M
Sale purchase of stock - -0.08M -0.06M 0.00M -0.24M
Other cashflows from financing activities - -0.08M -0.01M -0.07M -0.07M
Change to netincome - - - - 0.49M
Capital expenditures 1.94M 0.00M 0.01M 0.00M 0.01M
Change in working capital 0.35M -0.13M -0.38M 0.09M 0.05M
Other non cash items 0.00M 0.13M 0.40M - 2.87M
Free cash flow - -2.54M -2.76M -3.28M 0.04M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
BGT
Bio-Gene Technology Ltd		 -0.00
6.25%		 0.01 - - 5.28 2.72 10.73 -2.71
CSL
CSL Ltd		 2.86
1.42%		 204.54 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.32
2.28%		 13.70 93.87 166.67 5.37 6.37 3.85 47.29
NEU
Neuren Pharmaceuticals Ltd		 -0.30
1.25%		 23.66 154.93 36.36 42.38 7.52 31.95 160.40
MSB
Mesoblast Ltd		 -0.07
3.69%		 1.96 - 454.55 23.43 3.36 18.28 -9.86

Profile*

Bio-Gene Technology Ltd

Bio-Gene Technology Limited, an agtech development company, engages in the development and commercialization of naturally derived insecticide products in Australia and internationally. Its products include Flavocide, a synthetically produced nature-identical compound; and Qcide, a natural plant-derived oil with high levels of tasmanone. The company has a research collaboration agreement with James Cook University for experiments demonstrating the value of pre-conditioning biomass prior to distillation; Cesar for assessing the insecticidal activity of its molecules against a range of insect species; Advanced Molecular Technologies; CSIRO for a chemistry development process; the Department of Agriculture and Fisheries, Queensland Government for assessing activity against grain storage pests; Eurofins; Grain Research Development Corporation; Pacific Discovery Services; Purdue University; Southern Cross University for chemical analysis of natural products; University of Florida; and University of Technology. It serves animal health, crop protection, grain storage, public health, and consumer applications. The company was incorporated in 1995 and is based in Melbourne, Australia.

400 Collins Street, Melbourne, VIC, Australia, 3000

61 3 9068 1062

https://www.bio-gene.com.au

Name Title Year Born
Mr. Richard Andrew Jagger B.Sc., BSC (HONS), GAICD, M.INTL.BUS MD, CEO & Director NA
Mr. Roger McPherson C.P.A., CPA, B.Bus, GAICD CFO & Company Sec. NA
Mr. Peter Donald May AFA1M, AFAIM, GAICD, M.B.A., MBA Exec. Director of R&D and Exec. Director NA
Mr. Roger McPherson B.Bus, C.P.A., CPA, GAICD Interim CFO & Company Secretary NA
Mr. Roger McPherson B.Bus, C.P.A., CPA, GAICD Interim CFO & Company Secretary NA
Mr. Peter Donald May AFA1M, AFAIM, GAICD, M.B.A., MBA Executive Director of Research & Development and Executive Director NA
Mr. Roger McPherson B.Bus, C.P.A., CPA, GAICD Interim CFO & Company Secretary NA
Mr. Peter Donald May AFA1M, AFAIM, GAICD, M.B.A., MBA Executive Director of Research & Development and Executive Director NA
Mr. Timothy Owen Grogan B.Sc., LLB MD, CEO & Director NA
Mr. Roger McPherson B.Bus, C.P.A., CPA, GAICD Interim CFO & Company Secretary NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…